WO2019046841A1 - Composés anioniques aliphatiques et composés oxydants de stabilité et d'efficacité améliorées pour une utilisation dans des compositions pharmaceutiques - Google Patents

Composés anioniques aliphatiques et composés oxydants de stabilité et d'efficacité améliorées pour une utilisation dans des compositions pharmaceutiques Download PDF

Info

Publication number
WO2019046841A1
WO2019046841A1 PCT/US2018/049302 US2018049302W WO2019046841A1 WO 2019046841 A1 WO2019046841 A1 WO 2019046841A1 US 2018049302 W US2018049302 W US 2018049302W WO 2019046841 A1 WO2019046841 A1 WO 2019046841A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sodium
oral care
care composition
component composition
Prior art date
Application number
PCT/US2018/049302
Other languages
English (en)
Inventor
Jaiprakash G. Shewale
William E. Cooley
James L. Ratcliff
Esmeralda Ann GARCIA-SMITH
Original Assignee
Micropure, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micropure, Inc. filed Critical Micropure, Inc.
Priority to RU2019114126A priority Critical patent/RU2019114126A/ru
Priority to AU2018241206A priority patent/AU2018241206A1/en
Priority to CN201880002869.6A priority patent/CN109843387A/zh
Priority to CA3020197A priority patent/CA3020197C/fr
Priority to EP18785801.4A priority patent/EP3474951A4/fr
Priority to US16/133,359 priority patent/US11406577B2/en
Publication of WO2019046841A1 publication Critical patent/WO2019046841A1/fr
Priority to US17/094,489 priority patent/US11433010B2/en
Priority to US17/752,568 priority patent/US20220280402A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A61K8/21—Fluorides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present disclosure relates generally to a multi-component composition comprising a combination of an aliphatic anionic compound and an oxidative compound.
  • Oxidative compounds interact with various cellular components, causing, for example, peroxidation and disruption of membrane layers, oxidation of oxygen scavengers and thiol groups, enzyme inhibition, oxidation of nucleosides, impaired energy production, and/or disruption of protein synthesis and, possibly, cell death.
  • Biomolecules produced by cells and various other chemical compounds also may be oxidized by the oxidative compounds.
  • hydrogen peroxide may be more effective in controlling Pseudomonas aeruginosa and Stenotrophomonas maltophilia than peracetic acid (PAA).
  • PAA peracetic acid
  • PAA may be more effective than chlorine dioxide (CIO 2 ) at preventing growth of Escherichia coli, Listeria monocytogenes, and Salmonella typhimurium.
  • CIO 2 chlorine dioxide
  • oxidative compounds may react chemically, such as with the hydroxy groups of alcohols and polyhydroxy compounds.
  • chlorine dioxide in aqueous solution with the desired pH range from about 6.0 to about 8.0 decomposes to the chlorite and chlorate ions.
  • Sodium chlorite is a common source of chlorine dioxide.
  • One such product may be a fluoride toothpaste composition.
  • it may be desirable to maintain and extend the stability of the active ingredient(s) (e.g., fluoride ion), and other excipients, such as flavor, including stabilized chlorine dioxide or sodium chlorite . Stability may be considered from the time of manufacture, through distribution and sale, to the time of intended use.
  • active ingredient(s) e.g., fluoride ion
  • other excipients such as flavor, including stabilized chlorine dioxide or sodium chlorite . Stability may be considered from the time of manufacture, through distribution and sale, to the time of intended use.
  • USP U.S. Pharmacopoeia
  • a multi-component composition is provided, as well as various formulations of the multi-component composition, including methods of administration and methods of use.
  • the multi-component composition comprises an aliphatic anionic compound and an oxidative compound.
  • the multi-component composition may comprise N-acyl sarcosinate and stabilized chlorine dioxide.
  • multi-component composition comprising: from about 0.01% to about 5.0% of an aliphatic anionic compound, based on a total weight of the multi- component composition; from about 0.001 to about 8% of an oxidative compound, based on a total weight of the multi-component composition; a buffering system, wherein pH of the multi-component composition is between 6.0 and 8.0; and water.
  • the aliphatic anionic compound facilitates stability of the oxidative compound.
  • the aliphatic compound facilitates efficacy of the composition.
  • the aliphatic anionic compound comprises, at least one of, N-acyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauryl isethionate, sodium laureth carboxylate.
  • the N-acyl sarcosinate is, at least one of, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, sodium oleoyl sarcosinate, or sodium stearoyl sarcosinate.
  • the oxidative compound comprises, at least one of, ammonium peroxydisulfate, carbamide (urea) peroxide, ferric chloride, hydrogen peroxide, potassium bromate, potassium chlorate, potassium perchlorate, potassium dichromate, potassium ferricyanide, potassium peroxymonosulfate, potassium persulfate, sodium bromate, sodium chlorate, sodium perchlorate, sodium chlorite, sodium hypochlorite, sodium iodate, sodium perborate, sodium percarbonate, sodium persulfate, stabilized chlorine dioxide, strontium peroxide, and zinc peroxide.
  • carbamide (urea) peroxide ferric chloride
  • hydrogen peroxide potassium bromate
  • potassium chlorate potassium perchlorate
  • potassium dichromate potassium ferricyanide
  • potassium peroxymonosulfate potassium persulfate
  • sodium bromate sodium chlorate
  • sodium perchlorate sodium chlorite
  • sodium hypochlorite sodium iodate
  • sodium perborate sodium per
  • the multi-component composition is formulated in at least one of a mouth rinse, a gum, a gel, a paste, a cream, and a lozenge.
  • the multi-component composition comprises an orally acceptable aqueous vehicle comprising, at least one, a humectant, an abrasive, a pharmaceutically acceptable carrier, a fluoride ion source, and a thickening agent.
  • the multi-component composition oxidizes salivary biomolecules.
  • the multi-component composition oxidizes salivary biomolecules in 30 to 120 seconds of contact with saliva.
  • the salivary biomolecules are pyruvate and L-methionine.
  • the multi-component composition is applied to, at least one of, anal, aural, nasal, oral, and urogenital cavities.
  • the oxidative compound is destabilized after 3 months at 40 ⁇ 1 °C and 70-75% relative humidity or one year under ambient conditions.
  • the oxidative compound is stabilized chlorine dioxide, wherein less than 20% of the stabilized chlorine dioxide is degraded after 3 months at 40 ⁇ 1 °C and 70- 75% relative humidity or one year under ambient conditions.
  • an oral care composition comprising: from about 0.01 % to about 5.0% of an N-acyl sarcosinate, based on a total weight of the oral care composition; from about 0.001 to about 8% of an oxidative compound, based on the total weight of the oral care composition; a buffering system, wherein pH of the multi-component composition is between 6.0 and 8.0; and water, wherein the N-acyl sarcosinate provides enhanced stability and efficacy for the oxidative compound in the oral care composition.
  • the oral care composition further comprises, at least one of, a humectant, a whitening agent, a thickening agent, a fluoride ion source, a sweetening agent, an abrasive, a flavoring agent, a coloring agent, and a gelling agent.
  • the oral care composition is a dentifrice.
  • the buffering system comprises disodium hydrogen phosphate and sodium dihydrogen phosphate.
  • the oral care composition decreases regrowth of an oral polymicrobial biofilm.
  • the oral care composition effectively reduces regrowth of the oral polymicrobial biofilm in 24 hours.
  • the oral care composition enhances remineralization of tooth enamel.
  • the oral care composition oxidizes salivary biomolecules such as pyruvate and L-methionine in 30 to 60 seconds of contact with the saliva in the oral cavity.
  • the oral care composition provides an increased amount of available chlorite ion.
  • a method for enhancing fluoride uptake into an oral cavity comprising: preparing an oral care composition comprising from about 0.01 % to about 5.0% of an N-acyl sarcosinate, based on a total weight of the oral care composition, from about 0.001 to about 8% of an oxidative compound, based on the total weight of the oral care composition, a buffering system, wherein pH of the multi-component composition is between 6.0 and 8.0, water; and applying the oral care composition to the oral cavity.
  • the enhanced fluoride uptake into the oral cavity is increased by at least 2-fold.
  • the enhanced fluoride uptake into the oral cavity is increased by at least 4-fold.
  • the oral care composition enhances fluoride uptake.
  • a method to decrease regrowth of oral polymicrobial biofilm comprising: preparing an oral care composition comprising from about 0.01% to about 5.0% of an N-acyl sarcosinate, based on a total weight of the oral care composition, from about 0.001 to about 8% of an oxidative compound, based on the total weight of the oral care composition, a buffering system, wherein pH of the multi-component composition is between 6.0 and 8.0, water; and applying the oral care composition to an oral cavity.
  • the oral care composition decreases regrowth of oral polymicrobial biofilm.
  • FIG. 1 is a graph illustrating fluoride uptake of commercial products and an oral care composition according to an embodiment.
  • FIG. 2 is a graph illustrating tooth remineralization of commercial products to an oral care composition according to an embodiment.
  • FIG. 3 illustrates zero-order electronic absorption spectra of aqueous extracts of Toothpaste B.
  • FIG. 4 illustrates zero-order electronic absorption spectra of aqueous extracts of Toothpaste C.
  • acid source means a biological material, usually a particulate material, or which is itself acidic or produces an acidic environment when in contact with liquid water or oxy chlorine anion.
  • ambient conditions means approximately room temperature (e.g., 20-35 °C) and relative humidity of approximately ⁇ 70%.
  • a reasonable period of time means the time, ranging from months to years, depending upon the application, a composition may be expected to maintain a safe and efficacious amount of its combined ingredients.
  • shelf-life stable and “shelf-life stability” are used interchangeably and refer to the multi-component composition being deemed consumer acceptable after a defined period of time after its production (under ambient conditions).
  • bioavailability means to the absorption or penetration of the active agent(s) of the composition into the organic matter to which it is exposed and/or the absorption rate proportion of the dose of the composition that reaches the systemic circulation of the organic matter for which its use is intend. For example, when a composition is administered intravenously, its bioavailability is nearly 100%, while when the composition is administered topically, a fraction of the total composition reaches systemic circulation. Some embodiments described herein provide enhanced penetration or absorption of oxidative compounds when applied topically to organic matter.
  • bioavailability also refers to its availability for efficacy at the desired site and for efficacy that either intracellular, extracellular or within biofluids/biological fluids.
  • aliphatic anionic compounds means aliphatic compounds comprising anionic moiety that exhibit surface active properties, ionic interactions with other compounds, physical interaction, etc. as a result of combined physico-chemical properties of aliphatic and anionic structural moieties.
  • oxidative compounds means compounds exhibiting oxidation reaction of biomolecules such as organic acids, amino acids, sulfur compounds, precursors of sulfur compounds, proteins, enzymes etc.
  • biocidal means the property of inactivating or killing microorganisms, such as bacteria, algae, yeast, and fungi.
  • biocidal also refers to the effect of a composition as a treatment for reduction of bacterial or fungal or microbial growth or overgrowth in fluids or biofilm which may be associated with alleviating a diseased condition or state.
  • biostatic means the property of arresting the growth of microorganisms, such as bacteria, algae, yeast and fungi.
  • biostatic means to the effect of a composition in maintaining the polymicrobial mixture of a fluid or a biofilm, as in maintaining the oral ecology so that one or more organisms have not overgrown to enable inflection and disease.
  • Compositions with biostatic attributes are useful in health maintenance, wellness and prevention of infection and disease.
  • stabilized chlorine dioxide means an aqueous solution comprised of sodium chlorite or chlorite ion source and a compounds or compounds intended to inhibit or slow the degradation of the chlorite or chlorite ion source.
  • a biofilm means a biological aggregate that forms a layer on a surface, the aggregate comprising a community of microorganisms embedded in an extracellular matrix of polymers and/or other biocompounds such as glycoproteins.
  • a biofilm comprises a diverse community of microorganisms, including bacteria (aerobic and anaerobic), algae, protozoa, yeast, and fungi. While monospecies biofilms also exist, biofilms in vivo become polymicrobial as they develop overtime creating oxygen- scare environments where anaerobic pathogens thrive and where the biofilm matrix protects the polymicrobial mixture within from antimicrobial treatment.
  • buffering system means a system containing two or more agents characterized as an acid and its conjugate base or vice versa.
  • Suitable components of buffering system may include carbonates, borates, phosphates, imidazole, citrates, acetates and mixtures thereof, and further may include any of monosodium phosphate, disodium phosphate, trisodium phosphate, alkali metal carbonate salts, imidazole, pyrophosphate salts, acetic acid, sodium acetate, citric acid, and sodium citrate.
  • Exemplary compounds used in generating buffering system are described in more detail in Kirk & Othmer, Encyclopedia of Chemical Technology, Fourth Edition, Volume 18, Wiley-Interscience Publishers (1996).
  • pH modifying agent means an agent capable of modifying pH. pH modifying agents include acidifying agents to lower pH, basifying agents to raise pH and buffering agents to control pH within a desired range. Use or presence of single pH modifying agent may not result in a buffered composition.
  • a carrier means those components of a composition that are capable of being commingled to provide required physical consistency and consumer goodness properties without interaction with other ingredients.
  • orally acceptable carrier means a suitable vehicle or ingredient, which can be used to form and/or apply the present compositions to the oral cavity in a safe and effective manner.
  • compatible means that the components of the composition are capable of being commingled without interaction in any manner which would substantially reduce the stability of the oxidative compounds, ingredients required for the efficacy, the carrier and excipients, and the consumer qualities of the composition.
  • consumer goodness qualities include, but are not limited to, appearance, viscosity, taste, odor, abrasiveness, color, flavor, and moisturizing attributes of the compositions deemed desirable by consumers through consumer product testing or other such means. For example, it may be desirable that a tube of toothpaste produce a ribbon stripe of toothpaste on a toothbrush when squeezed and that the toothpaste composition is neither too firm to be squeezed easily from the tube nor too viscous so as not to hold or rest on the toothbrush ready or use.
  • plaque means a polymicrobial biofilm that forms on the surface of teeth.
  • dual phase composition means a composition wherein certain ingredients are contained in one part and other ingredients are contained separately in a second part at the time of manufacture and prior to use to prevent the reactivity of the oxidative compounds to the carrier and other excipients of the composition.
  • the bioavailability of dual phase compositions may be determined once the two phases are mixed at the time of use.
  • a difference between single phase and dual phase compositions may include how shelf-life is determined. Because the two phases of a dual phase compositions are combined just prior to usage, the shelf-life stability of dual phase compositions is the short period from the time of mixing just prior to use to the time of use which may occur immediately thereafter. Dual-phase compositions may not have the required attribute of maintaining stability of components from the time of manufacture to the time of usage precisely because the phases of the composition are not intended to be mixed until just prior to usage.
  • essentially free means a composition which is comprised of very low levels, below detection levels of commonly used analytical methods, of a specific ingredient or compound or molecule.
  • vehicle means an orally-acceptable dentifrice vehicle used to prepare a dentifrice composition comprising a water-phase, containing a humectant therein.
  • distifrice means paste, gel, powder, tablets, or liquid formulations, unless otherwise specified, that are used to clean the surfaces of the oral cavity.
  • teeth refers to natural teeth as well as artificial teeth or dental prosthesis.
  • an efficacious amount means any amount of the agent that may result in a desired biocidal or biostatic or chemical or physiological effect, a desired cosmetic effect, and/or a desired therapeutic biological effect.
  • an efficacious amount of an agent used for tooth whitening may be an amount that may result in whitening of a tooth with one or more treatments.
  • an efficacious amount of an agent used for wound treatment is an amount that may result in a statistically significant improvement in wound healing.
  • film means a layer of a material having two dimensions substantially larger than the third dimension.
  • a film may be a liquid or a solid material.
  • a liquid film can be converted into a solid film by curing, for instance, by evaporation, heating, drying, cross-linking, adhering, adduct formation, and like phenomena.
  • hard tissue means any toe and finger nail, hard keratinized tissue, hard tooth tissue, bone, tooth and the like, found in animals such as mammals.
  • irritating and “irritation” refer to the property of causing a local inflammatory response, such as reddening, swelling, itching, burning, or blistering, by immediate, prolonged, or repeated contact.
  • inflammation of a non-oral mucosal or dermal tissue in a mammal can be an indication of irritation to that tissue.
  • a composition may be deemed “substantially non-irritating” or “not substantially irritating,” if the composition is judged to be slightly or not irritating using any standard method for assessing dermal or mucosal irritation.
  • pharmaceutically acceptable is set forth broadly and refers without limitation to those compounds, materials, compositions and/or dosage forms which are, within the scope of sound medical judgment suitable for contact with the tissues of and/or for consumption by human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable risk/benefit ratio.
  • ppm means parts per million by weight or volume as applicable.
  • overgrowth refers to excessive concentrations of bacteria, algae, yeast, and/or fungi leading to inflammation, infection, pathogenesis and disease. Overgrowth may occur in biofilms and plaques containing polymicrobial mixtures of bacteria, algae, yeast, and/or fungi, such as those found in the biofilms associated with mucositis and with dental plaque. Overgrowths of pathogenic microbes within biofilms are known to increase significantly their resistance to treatment and increase the incidence of inflamed tissues, infection and disease.
  • prophylactic means treatment administered to a subject who does not exhibit signs of a disease or exhibits early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease.
  • range means the area of variation between upper and lower limits on a particular scale. It is understood that any and all whole or partial integers between any ranges set forth herein are included herein.
  • safe and effective amount and similar terms mean an amount of an ingredient, such as the amount of an oxidative compound, in composition of sufficient dosage to positively modify the condition to be treated, but low enough to be safe for humans and animals to use without serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical/dental judgment. "Safe and effective” pertains not only to the dosage amount but also the dosage rate (rate of release) of the oxidative compound applied in treatment.
  • the safe and effective amount of oxidative compound in a composition may vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the specific form (e.g., salt) of the oxidative compound employed, and the particular vehicle from which the oxidative compound is applied.
  • single phase composition means a composition wherein all ingredients are composed in a single container at the time of composing and are not mixed with other ingredients subsequently.
  • single phase compositions are ready for use at any time during their shelf-life without further preparation or mixing.
  • the bioavailability of single phase compositions may be determined at any point during their useful shelf-life.
  • stability means the prevention of a reaction, reduction or degradation of components, such as of oxidative compounds, comprised in a multi- component composition.
  • a multi-component composition may be “stable” if the oxidative compounds of the multi-component composition are not reactive with each other for a reasonable period of time.
  • a multi-component composition may stable if it maintains consumer qualities and exhibits less than 35% loss of the oxidative compounds for a period of 24 months at about 25 °C (ambient temperature) or 6 months at an accelerated temperature of 40° ⁇ 2 °C and 75% ⁇ 5% Relative Humidity (RH).
  • shelf-life means the length of time compositions maintain the desired stability of the oxidative compounds and the consumer qualities of the composition.
  • a target or stable shelf life for a composition may not comprise more than 35% loss in the concentration of oxidative compound in 6 months at 40 ⁇ 2 °C and 75% ⁇ 5% RH, which is equivalent to 2 years of shelf life at room temperature.
  • terapéutica means intended to be administered to a subject who exhibits signs of pathology for the purpose of diminishing or eliminating those signs.
  • topical composition means a product which is not intentionally ingested or otherwise applied without recovery for purposes of systemic administration of therapeutic agents, but is retained in the anal, aural, oral, nasal, ocular, or urogenital cavities or upon the skin or other outer surfaces of the body, or upon an area of affected soft tissue for a time sufficient to contact substantially all of the surfaces and/or tissues for purposes of administration and delivery of therapeutic agents.
  • wound means a laceration, abrasion, puncture, burn, and/or other injury to any one or more soft and/or hard tissue.
  • Exemplary tissues considered for such wound treatment include mucosal tissue and dermal tissue including epidermal tissue, dermal tissue, and subcutaneous tissue (also called hypodermis tissue).
  • a wound also encompasses a laceration, a puncture, and/or an avulsion of a fingernail or toenail.
  • a wound can penetrate the tissue partially or completely.
  • a wound can arise accidently or intentionally, e.g., a surgical wound.
  • dispersing agent means a compound that improves the separation of particles and prevents settling or clumping of an ingredient(s) in a multicomponent composition.
  • emollient agent means a compound that reduces the loss of water from a composition.
  • sustained release or emulsifying agent means a compound that achieves uniform dispersion of an ingredient(s) in a multicomponent composition.
  • fragment means a compound that provides a pleasing scent or order similar to perfume to a composition.
  • cooling agent means a compound that provides a cooling, soothing, or pleasant feeling when a composition is topically applied to hard and soft tissues.
  • warming agent means a compound that provide an olfactory sensation, especially warm sensation. Warming agents are often desired in various cosmetic preparations, such as shaving creams, hand lotions, body lotions, facial preparations, including masks, depilatories.
  • humectant means a compound that preserves moisture in a composition.
  • Some embodiments described herein include one or more compounds such as cellulose gum, carboxymethylcellulose, pectin, guar gum, xanthan gum, N-acyl sarcosinate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate.
  • thickener means a compound that increases viscosity of a composition.
  • excipient means a compound that provides physical and consumer goodness properties to a composition for its acceptance.
  • properties are viscosity, appearance, flavor, color, thickness, sweetness, gel like structure, preservative, uniform suspension or combinations thereof.
  • abrasive agent means a compound that helps to remove coating (or deposits) from hard or soft tissues, such as that on a tooth surface while brushing using a composition, such as a toothpaste.
  • desensitizing agent means a compound that helps reduce or alleviate sensitivity and pain.
  • a desensitizing agent in a topical resin, varnish, toothpaste or mouthwash may occlude dentin tubules or may desensitize nerve fibers, blocking the neural transmission.
  • the multi-component composition comprises an oxidative compound.
  • an oxidizing compound comprises at least one of a low-molecular-weight compound, a compound of suitable size and properties to permit diffusion or uptake through cell wall to react with internal cell components, and a compound which stimulates apoptotic or necrotic cell death.
  • the oxidizing compound includes compounds having a low oxidizing threshold, indicating that the selected oxidizing compounds interact strongly with its target by chemical rather than physical means.
  • the oxidative compound comprises, at least one of, chlorine dioxide or a chlorite ion source, such as stabilized chlorine dioxide, a chlorite salt, ammonium peroxydisulfate, , carbamide (urea) peroxide, ferric chloride, hydrogen peroxide, potassium bromate, potassium chlorate, potassium perchlorate, potassium dichromate, potassium ferricyanide, potassium peroxymonosulfate, potassium persulfate, sodium bromate, sodium chlorate, sodium perchlorate, sodium chlorite, sodium hypochlorite, sodium iodate, sodium perborate, sodium percarbonate, sodium persulfate, strontium peroxide, zinc acetate, zinc peroxide, zinc chloride or the like.
  • chlorine dioxide or a chlorite ion source such as stabilized chlorine dioxide, a chlorite salt, ammonium peroxydisulfate, , carbamide (urea) peroxide, ferric chloride, hydrogen peroxide, potassium bromate, potassium chlor
  • a multi-component composition may comprise from about
  • the multi-component composition may include from about 0.005% to about 4.0% oxidative compound. In further embodiment, the multi- component composition may include from about 0.005% to about 3.0% oxidative compound.
  • the multi-component composition includes from about
  • the multi-component composition comprises an aliphatic anionic compound.
  • the aliphatic anionic compound comprises water-soluble salts having from about 8 to 20 carbon atoms in an alkyl radical, such as taurates, sodium lauryl sulfoacetate, sodium lauryl isethionate, and sodium laureth carboxylate.
  • the aliphatic anionic compound comprises an N-acyl sarcosinate compound.
  • N-acyl sarcosinates may comprise the following general structure: , where R is typically a fatty acid of chain length Cg to C2 0 .
  • N-acyl sarcosinates may include lauroyl sarcosinate, cocoyl sarcosinate, myristoyl sarcosinate, oleoyl sarcosinate, stearoyl sarcosinate and other such compounds identifiable to a person skilled in the art.
  • the aliphatic anionic compound are provided in the form of a salt or a pharmaceutically accepted salt, such as, sodium lauroyl sarcosinate, sodium lauryl sulfoacetate, sodium lauryl isethionate, sodium laureth carboxylate, sodium cocoyl sarcosinate, and sodium myristoyl sarcosinate.
  • a multi-component composition comprising from about 0.001% to about 20.0% aliphatic anionic compound. In further embodiments, the multi-component composition includes from about 0.001% to about 10% of an aliphatic anionic compound. In further embodiments, the multi-component composition may include from about 0.001% to about 5.0% of an aliphatic anionic compound. In further embodiments, the multi-component composition includes from about 0.001% to 1% of an aliphatic anionic compound. In further embodiments, the multi-component composition includes from about 0.01% to 1% of an aliphatic anionic compound. In further embodiments, the multi- component composition includes from about 0.01% to 5% of an aliphatic anionic compound.
  • the multi-component composition includes from about 0.2% to 5% of an aliphatic anionic compound. In further embodiments, the multi-component composition includes from about 0.5% to about 5% of an aliphatic anionic compound.
  • the multi-component composition comprises a carrier.
  • suitable carrier(s) comprise those that satisfy various considerations based on compatibility with the other ingredients required for the efficacy, consumer qualities, cost, and contribution to shelf stability.
  • the selected carrier does not substantially reduce either the stability of the composition or its efficacy.
  • suitable carriers variously include gelling agents, whitening agents, flavoring agents and flavoring systems, coloring agents, abrasive agents, foaming agents, desensitizing agents, dispersants, humectants, sweetening agents analgesic and anesthetic agents, anti-inflammatory agents, anti-malodor agents, anti-microbial agents, anti-plaque agents, anti-viral agents, biofilm disrupting, dissipating or inhibiting agents, cellular redox modifiers, antioxidants, cytokine receptor antagonists, dental anti-calculus agents, fluoride ion sources, hormones, metalloproteinase inhibitors, enzymes, immune-stimulatory agents, lipopolysaccharide complexing agents, tissue growth factors, vitamins and minerals, water, and mixtures thereof.
  • the multi-component composition comprises a buffering system.
  • the buffering system may be required to achieve and maintain a pH of the multi-component composition in the range required to prevent the degradation of the oxidative compound in the multi-component composition.
  • the buffering system may comprise an acid and its conjugate base or a base and its conjugate acid.
  • the buffering system may comprise an organic acid and its conjugate base or an organic base and its conjugate acid.
  • the buffering system may comprise an inorganic acid and its conjugate base or an inorganic base and its conjugate acid.
  • the buffering system comprises an organic acid and an inorganic base or an inorganic acid and an organic base.
  • the buffering system maintains a composition pH at a range from about 6.0 to about 8.5.
  • a buffering system may also be useful to achieve consumer goodness properties.
  • a buffering system generally differs from a single pH modifying agent used to reduce the pH of a composition or raise the pH of a composition.
  • a buffering system comprises from about 0.2% to about 4.0%, from about 0.05% to about 0.5%, from about 0.2% to about 2.0%, or from about 0.7% to about 4.2%, or from about 0.7% to about 2.2% of a base compound.
  • the buffering system comprises from about 0.01% to about 4.0%, from about 0.01% to about 0.10%, from about 0.01% to about 0.05%, from about 0.01% to about 0.05%, from about 0.04% to about 2.1% or from about 0.05% to about 2.2%, from about 0.06% to about 0.2%, from about 0.00% to about 0.1% of an acidic compound.
  • the multi-component composition includes one or more pH modifying agents.
  • pH modifying agents for use herein may include acidifying agents to lower pH, basifying agents to raise pH.
  • one or more compounds can provide a pH from about 2 to about 10, or from about 2 to about 8, or from about 3 to about 9, or from about 4 to about 8, or from about 5 to about 7, or from about 6 to about 10, or from about 6 to about 8, or from about 7 to about 8, or from about 7 to about 9, and any pH above or below this range or any fractional range in between.
  • Orally acceptable pH modifying agent including without limitation carboxylic, phosphoric and sulfonic acids, acid salts (e.g., monosodium citrate, disodium citrate, monosodium malate, etc.), alkali metal hydroxides such as sodium hydroxide, carbonates such as sodium carbonate, bicarbonates, sesquicarbonates, borates, silicates, phosphates (e.g., monosodium phosphate, trisodium phosphate, pyrophosphate salts, etc.), imidazole and mixtures thereof.
  • One or more pH modifying agents are optionally present in a total amount effective to adjust the composition to an orally acceptable pH range.
  • the multi-component composition may include from about 0.01 % to about 10% pH modifier agents based on a total weight of the oral care composition.
  • the pH modifier agents may be from about 0.01 %, 0.1 %, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or to about 10% by weight or volume of the multi-component composition.
  • a pharmaceutically acceptable carrier may be in an amount from about 0.01% to about 5%, from about 0.01% to about 3%, or from about 0.01 % to about 2%.
  • Use or presence of single pH modifying agent generally does not result a buffered composition.
  • the multi-component composition may further comprise one or more additional active ingredients.
  • an additional active ingredient may include one or more of the following additional ingredients: fluoride ion sources, antimicrobial agents, analgesic compounds, anti-inflammatory agents, anti-malodor agents, anti-plaque agents, anti-viral agent, biofilm disrupting, dissipation or inhibiting agents, hormones, enzymes, metalloproteinase inhibitors, immune-stimulatory agents, and numbing agents.
  • the multi-component composition comprises one or more excipients including any of water, abrasives, humectants, thickeners, sweeteners, moisturizers, flavors, colors, fillers, and extenders.
  • the multi-component composition comprises a pharmaceutically acceptable carrier and/or excipients.
  • Pharmaceutically -acceptable carriers include one or more compatible solid or liquid materials, including diluents or encapsulating substances, which are suitable for topical administration to the human or animal body and provide physical action or consumer-goodness characteristics acceptable to the user.
  • the pharmaceutical carriers and/or excipients may be combined with the oxidative compounds in a single phase multi-component composition without interaction in any manner that would reduce the stability of the oxidative compound, the consumer goodness qualities, the safety and effectiveness of the composition in treating or preventing anal, aural, oral, nasal, ocular, urogenital, foot, and skin disorders, or diseases of the skin or foot and the inflammation and infection of tissues therein.
  • a pharmaceutically acceptable carrier and/or excipient may be determined by the way the composition is to be introduced into the anal, aural, oral, nasal, ocular, or urogenital cavity, or to be applied topically in foot care and skin care.
  • the pharmaceutically acceptable carrier and/or excipient may depend on secondary considerations such as, but not limited to, consumer goodness qualities, costs and shelf-life stability.
  • the pharmaceutically acceptable carrier and/or excipients may be in an amount of from about 0.01% to about 30%, for example, from about 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or to about 10% by weight or volume of the multi- component composition.
  • the pharmaceutically acceptable carrier may be in an amount from about 0.01% to about 60%, from about 0.01% to about 30%, or from about 0.01% to about 20%.
  • the multi-component composition further comprises an abrasive agent.
  • Abrasives are useful as carriers of the multi-component compositions intended for specific oral and dermal applications and uses.
  • abrasive materials provide physical abrasion between toothbrush and teeth to clean pellicle, cuticle, biofilm, plaque, stain, and calculus, while also contributing to the structure of an embodiment and maintaining stability of the overall formulation.
  • the abrasive material is selected from a composition that does not excessively abrade skin, enamel, dentin, or other hard or soft tissues.
  • the abrasive agent comprises, for example, silicas, hydrated silicas, including gels and precipitates; insoluble sodium polymetaphosphate; hydrated alumina; calcium carbonate; calcium hydrogen orthophosphate dihydrate (known in the trade as "dicalcium phosphate”); tricalcium phosphate, calcium polymetaphosphate, sodium bicarbonate and resinous abrasive materials.
  • a mixture of abrasives may also be used.
  • the abrasive is present in an amount from about 0.01% to about 70%, for example, from about 0.01%, 0.1%, 1%, 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50% or to about 70% by weight of the multi-component composition.
  • the abrasive agent may be present in an amount from about 6% to about 70%, from about 10% to about 50%, or from about 6% to about 70%, from about 20% to about 70%.
  • such as nasal or oral sprays, oral or vaginal rinses and non-abrasive gel compositions, such as those used in wound healing may comprise no abrasive.
  • the multi-component composition comprises an alkali metal bicarbonate salt.
  • Alkali metal bicarbonate salts are soluble in water and, unless stabilized, tend to degrade oxidative compounds in an aqueous system.
  • Sodium bicarbonate also known as baking soda, may be included as an alkali metal bicarbonate salt into the multi-component composition.
  • the alkali metal bicarbonate salt is present in an amount of from about 0.01% to about 70%, for example, from about 0.01%, 0.1%, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, or to about 70% by weight of the multi-component composition.
  • the alkali metal bicarbonate salt may be in an amount from about 0.5% to about 70%, from about 1% to about 50%, or from about 5% to about 50%.
  • the multi-component composition further comprises additional agents which reduce dental plaque, tartar and calculus from teeth.
  • the additional agents comprise zinc ions, a cationic material, such as guanides and quaternary ammonium compounds, as well as non-cationic compounds such as halogenated salicylanilides.
  • an anti-calculus agent is provided, and may be comprised of a pyrophosphate ion source such as pyrophosphate salts.
  • the pyrophosphate salts may include in the multi- component composition may include di-alkali metal pyrophosphate salts, tetra-alkali metal pyrophosphate salts, and mixtures thereof.
  • Disodium dihydrogen pyrophosphate Na2H 2 P 2 0 7
  • tetrasodium pyrophosphate Na 4 P 2 0v
  • tetrapotassium pyrophosphate K4P2O7
  • the pyrophosphate salt may be present in one of three ways: predominately dissolved, predominantly undissolved, or a mixture of dissolved and undissolved pyrophosphate.
  • the multi-component composition comprises a mixture of dissolved and undissolved pyrophosphate salts.
  • Polyolefin phosphates include those wherein the olefin group contains 2 or more carbon atoms.
  • Other useful materials include synthetic anionic polymers, including poly-acrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez ® ), as well as, e.g., polyamino propane sulfonic acid (AMPS), zinc citrate trihydrate, poly -phosphates (e.g., tripolyphosphate; hexametaphosphate), diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof.
  • synthetic anionic polymers including poly-acrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez ® ), as well as, e.g., polyamino propane sulfonic acid (AMPS), zinc citrate trihydrate, poly -phosphates (e.g., tripolyphosphate; hexametaphosphate), diphosphonates (e
  • the anti-calculus agent may be present in an amount of from about 0.01% to about 50%, for example, from about 0.01%, 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, or to about 50% by weight of the multi-component composition. In other embodiments, the anti-calculus agent may be present in an amount from about 0.5% to about 25%, from about 1% to about 25%, or from about 5% to about 50%.
  • a multi-component composition comprises a coloring agent.
  • the consumer goodness quality of coloring are not degraded by the oxidative compounds and vice versa. Coloring enables the consumer to more readily ascertain usage and dosage. Certain colors of the composition may be deemed undesirable for certain anal, aural, ocular, oral or urogenital applications.
  • a coloring agent includes, FD&C Blue No. 1 or titanium dioxide. Suitable coloring agents include those that are stable and do not degrade in the presence of the oxidative compounds and do not degrade oxidative compounds.
  • the coloring agent may be in an amount of from about 0.01% to about 10%, for example, from about 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or to about 10% by weight or volume of the multi-component composition. In other embodiments, the coloring agent may be in an amount from about 0.5% to about 10%, from about 1% to about 10%, or from about 0.01% to about 2%, or from 0.8% to about 1.1%.
  • a multi-component composition comprises a cooling and/or warming agent.
  • Suitable cooling and/or warming agents may be those that are stable and do not degrade the presence of the oxidative compound within the compositions, such as those described in U.S. 2017/0877199 to Patton.
  • the multi-component composition further comprises a flavoring agent and/or flavoring systems.
  • Suitable flavoring agents include those that are stable and do not degrade in the presence of the oxidative compounds and do not degrade oxidative compounds.
  • Suitable flavoring systems may include an emulsified flavoring agent for protecting the flavoring agent from degradation.
  • Suitable flavoring systems include those that are taught by U.S. 2012/0164084.
  • a flavoring agent comprises menthol, mint oil, emulsified mint oil, bubblegum flavor, watermelon flavor or different types of berry flavor.
  • the flavoring agent may be present in an amount of from about 0.01% to about 10%, for example, from about 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or to about 10% by weight or volume of the multi-component composition. In some other embodiments, the flavoring agent may be in an amount from about 0.25% to about 1.2%, from about 1.1% to about 10%, or from about 1.1% to about 7.5%.
  • the multi-component composition comprises a sweetening agent.
  • Suitable sweetening agent may be stable and not degrade in the presence of oxidative compounds or degrade oxidative compounds.
  • the sweetening agent comprises sucrose, aspartame, acesulfame, stevia, saccharin; saccharin salts, especially sodium saccharin; sucralose, sodium cyclamate, and mixtures thereof.
  • sweetening agents that are polyhydroxy alcohols such as xylitol, mannitol, and sorbitol.
  • a multi-component composition is free of polyhydroxy sweeteners such as xylitol, mannitol, and sorbitol.
  • a sweetening agent comprises sucrose, sucralose, acesulfame, aspartame, cyclamate, or saccharin.
  • the sweetener may be in an amount of from about 0.01% to about 0.5%, for example, from about 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, or to about 0.5% by weight or volume of the multi-component composition.
  • the sweetener may be in an amount from about 0.05% to about 0.5%, from about 0.1% to about 0.2%, from about 0.01% to about 0.5%, or from 0.01% to about 0.2%.
  • a multi-component composition further comprises one or more humectants.
  • Suitable humectants include those that include at least one of the following: serves to keep pastes and gels and suspensions from hardening or losing their consumer goodness qualities when exposed to air, to add to the compositions a moist feel to the consumer goodness qualities and, for particular humectants orally applied, to impart desirable sweetness of flavor, such as toothpaste compositions.
  • the humectant comprises polyhydroxy alcohols, including arabitol, erythritol, glycerol, maltitol, mannitol, sorbitol, and/or xylitol.
  • humectants such as glycerol, sorbitol and other polyhydroxy compounds have been known to cause degradation of oxidative compounds when comprised in the same single phase, in accordance with various aspects, it has been discovered that a single phase multi-component composition comprising the combination of an oxidative compound and an aliphatic anionic compound (e.g., an N-acyl sarcosinate compound) that exhibit humectant type in terms of providing consistency to the composition and surface active properties may not experience significant degradation of the oxidative compound.
  • sorbitol may be a humectant comprised in the multi-component composition.
  • the humectant may be present in an amount of from about 0.001% to about 70%, for example, from about 0.001%, 0.01%, 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%, or to about 70% by weight or volume of the multi-component composition. In some other embodiments, the humectant may be in an amount from about 1% to about 15%, from about 15% to about 55%, or from about 25% to about 55%.
  • the multi-component composition comprises a fluoride ion source.
  • the multi-component composition includes free fluoride ions or covalently bound fluorine in a form that may be hydrolyzed by oral enzymes to yield free fluoride ions.
  • Free fluoride ions comprise sodium fluoride, silver diamine fluoride, stannous fluoride, or indium fluoride.
  • Covalently bound fluorine, which can be enzymatically hydrolyzed to yield free fluoride may be provided by sodium monofluorophosphate.
  • sodium fluoride may be comprised in the multi-component composition as the source of free fluoride ions.
  • a fluoride ion source is used as a component in a multi-component composition
  • a fluoride ion source as disclosed in, U. S. Pat. Appl. No. 2011/0318282 may be preferred.
  • a fluoride ion source in a single phase multi-component composition, comprising for example the combination of an oxidative compound and an aliphatic anionic compound (e.g., an N-acyl sarcosinate compound), such composition may resist significant degradation of the oxidative compound and promote shelf-life and shelf-stability.
  • a multi-component composition comprises a fluoride ion source, an aliphatic anionic compound (e.g., an N-acyl sarcosinate compound), and an oxidative compound.
  • the composition may remain stable for a reasonable period of time.
  • the composition may maintain the capacity for the oxidative compounds of the composition to react or activate upon use.
  • the composition may enhance the capacity for the oxidative compounds to increase penetration of bacteria and biofilms as opposed to comparable compositions not containing an aliphatic anionic compound.
  • the fluoride ion source comprises at least one of an indium fluoride, sodium fluoride, silver diamine fluoride, stannous fluoride, or sodium monofluorophosphate.
  • a multi-component composition further comprises a source of fluoride ion providing fluoride ions from about 0 ppm to about 5000 ppm, or from about 50 ppm to about 3500 ppm, from about 500 ppm to about 3500 ppm.
  • the fluoride ion source may be in an amount of from about 0% to about 2.0%, for example, from about 0.01 %, 0.1 %, 0.15%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, or to about 2.0% by weight or volume of the multi-component composition.
  • the fluoride ion source may be in an amount from about 0.0% to about 0.03%, from about 0.0% to about 0.7%, from about 0.1% to about 0.8%, from about 0.01 % to about 0.07%, or from about 0.0% to about 0.8%.
  • a composition is referred as fluoride-free when the source of fluoride ion source is 0% or when the composition is essentially free of fluoride as described herein.
  • a multi-component composition further comprises a thickening or binding agent.
  • the thickening or binding agent may provide desired consumer goodness qualities appropriate to the multi-component composition, such as the desirable consistency or viscosity of the composition, to provide desirable dosage and at a rate of release desired of the oxidative compounds upon use, and to adhere to hard or soft tissues in a topical application.
  • thickening or binding agents include carboxyvinyl polymers, seaweed derivatives such as carrageenan, hydroxyethyl cellulose, laponite, powdered polyethylene, and water soluble salts of cellulose ethers such as sodium carboxymethylcellulose and sodium carboxymethyl hydroxyethyl cellulose.
  • Natural gums such as gum karaya, guar gum, xanthan gum, gum arabic, and gum tragacanth can also be used.
  • Colloidal magnesium aluminum silicate or finely divided silica may be used as part of the thickening or binding agent to further improves texture.
  • Higher concentrations of thickening agents can be used for chewing gums, lozenges (including breath mints), sachets, non-abrasive gels and gels intended for use in wound-healing, vaginal or oral disease.
  • the thickening or binding agent may be present in an amount of from about 0% to about 15%, for example, from about 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or to about 15% by weight or volume of the multi-component composition. In some other embodiments, the thickening or binding agent may be in an amount from about 0.1 % to about 15%, from about 2.0% to about 10%, from about 4% to about 8%, from about 1.0% to about 4.0%, or from about 5.0% to about 7.0%.
  • the multi-component composition further comprises a whitening and/or opacifying agent.
  • the whitening and/or opacifying agent comprises a non- hydrogen peroxide whitening agent.
  • titanium dioxide may be included to a multi-component composition to achieve whiteness or opaqueness of the multi-component composition.
  • a whitening and/or opacifying agent comprises a peroxide, metal chlorite, perborate, percarbonate, peroxyacid, persulfate, and combinations thereof. Suitable peroxide compounds include hydrogen peroxide, urea peroxide (carbamide peroxide), calcium peroxide, and mixtures thereof.
  • the multi- component composition may be essentially free of glycerin and/or polyhydroxy compounds.
  • the whitening and/or opacifying agent may be present in an amount of from about 0% to about 20%, for example, from about 0.01 %, 0.1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, or to about 20% by weight or volume of the multi-component composition.
  • the fluoride ion source may be in an amount from about 0.01 % to about 20%, from about 0.5% to about 10%, or from about 4% to about 7%.
  • the multi-component composition further comprises water.
  • Water may provide the remaining weight percent of the multi-component compositions (i.e., the weight percent not attributed to the other components described herein).
  • Water employed in the multi-component compositions used as commercially suitable topical compositions can be of low ion content and essentially free of organic impurities. Water can comprise up to about 98% of the composition, particularly for mouthwashes, mouth rinses and mouthwashes, oral and nasal sprays, vaginal douches, and soaks, and preferably from about 5% to about 60%, by weight of the aqueous compositions herein. These amounts of water include the free water which is added to the composition plus that which is introduced with other materials added to the composition.
  • the multi-compound composition include powders, lozenges and chewing gum, are of course substantially dry or contain only a small amount of water.
  • the multi-component composition further comprises a surfactant.
  • Surfactants may be anionic, cationic, non-ionic, or amphoteric (zwitterionic). These may be useful as foaming agents in oral care, cosmetic, healthcare, and pharmaceutical products. Such foaming agents may also useful in the retention of sanitizing and moisturizing agents in skin care products, such as shaving creams and foams.
  • the surfactant may be in an amount of from about 0% to about 15%, for example, from about 0.01%, 0.1%, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, or to about 15% by weight or volume of the multi-component composition. In some other embodiments, the surfactant may be in an amount from about 0.1% to about 15%, from about 2.0% to about 10%, or from about 4% to about 8%.
  • the multi-component composition further comprises a desensitizing agent.
  • the desensitizing agent may be provided for temporary relief from pain to hard or soft tissues.
  • the desensitizing agent comprises compounds such as strontium chloride, strontium acetate, arginine, hydroxyapatite, nano-hydroxy apatite (nano-HAp), calcium sodium phosphosilicate, potassium chloride or potassium nitrate.
  • the compositions may be essentially free of compounds, such as sodium lauryl sulfate, that irritate sensitive body cavities such as anal, nasal, ocular, oral, and urogenital. Examples of sensitivities and resultant diseases oral cavity include canker sores, oral mucositis, and dry mouth.
  • the multi-component composition further comprises a preservative.
  • the preservative comprises a methyl paraben, propyl paraben, disodium EDTA, benzyl alcohol, benzoic acid, or sodium benzoate.
  • the preservative may be present in an amount of from about 0% to about 2%, for example, 0.01%, 0. 1%, 1%, or 2% by weight or volume of the multi-component composition.
  • the surfactant may be in an amount from about 0.1 % to about . 15%, from about 0.2% to about 1 %, from about 0.01 % to 0.5%, or from about 0.4% to about 0.8%.
  • the multi-component composition does not contain a polyhydroxy compound.
  • Polyhydroxy compounds are known to react and degrade oxidative compounds and compounds, such as stabilized chlorine dioxide, and therefore, may be excluded from the multi-component composition.
  • Polyhydroxy compounds may include glycerin, alcohols, polyethylene glycols, xylitol, and sorbitol.
  • the multi-component compositions described herein are single- phase composition.
  • the multi-component composition is configured to form a dentifrice.
  • the multi-component composition is configured to form an oral rinse.
  • the multi-component composition is an oral care composition, such as an oral spray, oral gel, denture or dental appliance soak, toothbrush soak, or a solution intended for use in an oral irrigation device.
  • the multi-component composition is formulated as a cosmetic.
  • Cosmetic compositions for example, a solid cosmetic composition, such as a gel, soft-solid or semisolid (cream), or stick
  • a base composition containing at least one silicone fluid (for example, silicone liquids such as silicone oils) which is thickened using a siloxane-based polyamide as a gelling agent; a carrier in which cosmetically active materials are incorporated; and at least one active ingredient to provide the activity for such cosmetic composition.
  • the cosmetic compositions are transparent (clear), including solid transparent (clear) compositions.
  • the cosmetic composition is formulated that the final composition is opaque.
  • the cosmetic composition is formulated so that the final composition is not-transparent.
  • the cosmetic may further comprise one or more additional agents as carriers, selected from one or more of abrasive polishing materials, alkali metal bicarbonate salts, analgesic and anesthetic agents, anti-inflammatory agents, anti-malodor agents, anti -microbial agents, anti-plaque agents, and anti-viral agents, biofilm disrupting, dissipating or inhibiting agents, buffers and buffering systems, cellular redox modifiers and antioxidants, coloring agents and coloring systems, cytokine receptor antagonists, dental anti-calculus agents, hormones, metalloproteinase inhibitors, immune-stimulatory agents, lipopolysaccharide complexing agents, tissue growth factors, titanium dioxide, vitamins and minerals, and mixtures thereof.
  • additional agents as carriers selected from one or more of abrasive polishing materials, alkali metal bicarbonate salts, analgesic and anesthetic agents, anti-inflammatory agents, anti-malodor agents, anti -microbial agents, anti-plaque agents, and anti-viral
  • the multi-component composition may be combined with one or more such agents in a single phase delivery system to provide combined effectiveness, while maintaining the stability of the oxidative compound (e.g., stabilized chlorine dioxide).
  • the oxidative compound e.g., stabilized chlorine dioxide
  • the multi-component composition may be specifically formulated for use in humans and animals, for example in the form of rinses, gels, pastes, creams, washes, sprays, lozenges, therapeutic floss, tape, patches, compresses, or strips, for use in skin care, oral care, urogenital care, foot care, wound healing and as a solution used in irrigation devices for use in the oral and other body cavities.
  • the multi-component composition has consumer goodness qualities.
  • ingredients are selected for an oral care composition that achieves a desirable range of viscosity to ensure product manufacturability, applicability, stability, and quality, as well as consumer acceptance.
  • the multi-component composition may be phase stabile.
  • Phase stability may refer to an oral care composition visually (i.e., to the unaided eye) having no liquid separation from the composition's body over a defined period of time under ambient conditions.
  • Such phase stable multi-component compositions may resist syneresis.
  • a toothpaste embodiment herein may be less abrasive on teeth than a similar composition without the inclusion of aliphatic anionic compounds.
  • consumer goodness qualities may comprise where the composition retains clarity (clear, water-like appearance); however clarity is not limited by the presence of a color in the composition if a color is intended.
  • a vaginal douche embodiment should not sting, stain, burn or otherwise cause irritation to the user, has a viscosity that enables ease of use, and has a pleasing fragrance or no fragrance at all following use.
  • Consumer goodness qualities of various embodiments herein may vary for use with other animals. For example, an oral rinse for dogs may have preferably a meat flavor while one for humans may have a mint flavor.
  • the multi-component composition is suitable for a variety of indications, including treatment and prevention of oral or vaginal malodor, as well as ocular, nasal and skin care and other topical uses.
  • Suitable topical indications include anal, aural, oral, nasal, ocular, urogenital, foot-care and skin-care conditions and diseases.
  • the composition may be suitable for select indications, including antimicrobial, antiseptic, antioxidant, bactericidal and bacteriostatic, biofilm penetration, biofilm dissipation and reduction, coagulant, deodorant, desensitizing, disinfectant, fungicidal and fungistatic, herbicidal, tissue damage reduction, bleaching, stain removal, and tooth whitening.
  • Compositions herein are suitable for use in a variety of forms, including rinses, gels, pastes, creams, washes, sprays, lozenges, floss, tape, patches, bandages, compresses, wraps, and strips.
  • the multi-component composition maintains stability and consumer goodness. In embodiments, stability and consumer goodness is maintained from manufacture of the composition through about twelve (12) months of storage under ambient conditions. In embodiments, the multi-component composition may exhibit no more than 10% loss in stabilized chlorine dioxide in three (3) months at 40 ⁇ 2 °C and 75% ⁇ 5% relative humidity (RH) which may be equivalent to twelve (12) months of storage at room temperature. In embodiments, the multi-component composition may exhibit no more than 20% loss in stabilized chlorine dioxide in in three (3) months at 40 ⁇ 2 °C and 75% ⁇ 5% relative humidity (RH).
  • RH relative humidity
  • the multi-component composition may exhibit no more than 30% loss in stabilized chlorine dioxide in three (3) months at 40 ⁇ 2 °C and 75% ⁇ 5% relative humidity (RH). In some embodiments, the multi-component composition may exhibit no more than 40% loss in stabilized chlorine dioxide in three (3) months at 40 ⁇ 2 °C and 75% ⁇ 5% relative humidity (RH) In another embodiment, storage of the composition under accelerated conditions (typically 40 ⁇ 2 °C and 75% ⁇ 5% relative humidity, RH) can project real time suitability of a composition for consumer use, anticipating the time of manufacture, transit from point of manufacture to wholesaler, from wholesaler to retailer, from retailer to consumer, plus the anticipated storage time by the consumer as the product is consumed.
  • RH relative humidity
  • compositions may comprise: from about
  • a chlorite ion source such as sodium chlorite, from about 0.7% to about 4.2% a base such as disodium hydrogen phosphate or trisodium phosphate, from about 0.05% to about 2.20% an acid or a buffering salt on the acidic side, such as sodium dihydrogen phosphate, citric acid, or acetic acid, from about 0.2% to about 5.0% an N-acyl sarcosinate compound, such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate, from about 0.8% to about 1.1% coloring agent such as FD&C Blue No.
  • abrasive agent such as hydrated silica, calcium hydrogen phosphate, alumina, sodium bicarbonate, from about 0.05% to about 0.5% sweetening agent such as sucrose, sucralose, acesulfame, aspartame, cyclamate, or saccharin, from about 0.025% to about 1.2% flavoring agent such as menthol, mint oil, emulsified mint oil, tropical fruit, watermelon, bubblegum, strawberry or berry flavor, from about 0.0% to about 0.8% fluoride ion source or source of releasable fluoride ion, such as sodium fluoride, silver diamine fluoride, sodium monofluorophosphate, or stannous fluoride, and water to 100%, thereby
  • Various single-phase oral care gel compositions may comprise: from about 0.005% to about 2.0% chlorite ion source such as sodium chlorite, from about 0.7% to about 4.2% a base, such as disodium hydrogen phosphate or trisodium phosphate, from about 0.05% to about 2.20% an acid or a buffering salt on the acidic side, such as phosphoric acid, sodium dihydrogen phosphate, citric acid, or acetic acid, from about 0.2% to 5.0% an N-acyl sarcosinate compound, such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate, from about 5.0% to about 7.0% gelling agent such as gelatin, pectin, xanthan gum, guar gum, cellulose gum, other natural or synthesized gums, or sodium carboxymethyl cellulose, from about 0.05% to about 0.5% sweetening agent such as sucrose, acesulfame, aspart
  • Various single-phase oral care rinse compositions may comprise: from about 0.005% to about 2.0% of chlorite ion source such as sodium chlorite, from about 0.2% to about 4.0% a base, such as disodium hydrogen phosphate or trisodium phosphate, from about 0.04% to about 2.10% an acid or a buffering salt on the acidic side, such as sodium dihydrogen phosphate, phosphoric acid, citric acid or acetic acid, from about 0.01% to about 1.0% an N- acyl sarcosinate compound such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate, from about 0.01% to about 0.2% sweetening agent such as sucrose, acesulfame, aspartame, cyclamate, sucralose, or saccharin, from about 0.025% to about 1.2% flavoring agent such as menthol, mint oil, emulsified mint oil, tropical fruit, bubbleg
  • the fluoride ion source is eliminated from the composition and the quantity of water is adjusted accordingly.
  • the fluoride ion source and the flavoring agents are eliminated from the composition.
  • the composition may comprise a buffering system and/or a flavoring system as described herein.
  • Various oral care spray formulation may comprise: from about 0.005% to about 2.0% chlorite ion source such as sodium chlorite, from about 0.05% to about 0.5% a base such as disodium hydrogen phosphate, sodium citrate, or trisodium phosphate, from about 0.01% to about 0.05% an acid or a buffering salt on the acidic side, such as phosphoric acid, citric acid, acetic acid, or sodium dihydrogen phosphate, from about 0.01% to about 1.0% an N-acyl sarcosinate compound such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate, from about 0.01% to about 0.5% sweetening agent such as sucrose, acesulfame, aspartame, cyclamate, sucralose, or saccharin, from about 1.1% to about 7.5% flavoring agent such as menthol, mint oil, emulsified mint oil, watermelon, bubbleg
  • Exemplary Composition V Wound-Healing Gel/Ointment Embodiment
  • Various single-phase oral care gel compositions may comprise: from about 0.005% to about 2.0% chlorite ion source such as sodium chlorite, from about 0.7% to about 2.2% a base such as disodium hydrogen phosphate or trisodium phosphate, from about 0.06% to about 0.20% an acid or a buffering salt on the acidic side, such as sodium dihydrogen phosphate, citric acid, or acetic acid, from about 0.5 to 5.0% an N-acyl sarcosinate compound, such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate, from about 5.0% to about 7.0% gelling agent such as gelatin, pectin, guar gum, xanthan gum, cellulose gum, or sodium carboxymethyl cellulose, from about 0.025% to about 1.2% a cooling agent, such as menthol or emulsified mint oil, from about 0.1% to about 10% an emollient agent,
  • Various single-phase vaginal douche compositions preferably, comprise: from about 0.005% to about 2.0% a chlorite ion source such as sodium chlorite, from about 0.2% to about 2.0% a base such as sodium bicarbonate, disodium hydrogen phosphate or trisodium phosphate, from about 0.00% to about 0.10% an acid or a buffering salt on the acidic side, such as boric acid, citric acid, acetic acid, or sodium dihydrogen phosphate, from about 0.001% to about 1.0% an N-acyl sarcosinate compound such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, or sodium myristoyl sarcosinate, from about 0.1% to about 10% an emollient agent, such as mineral oil, from about 0.1% to about 5% a suspending or emulsifying agent, such as a polysorbate or poloxamer, from 0.01% to 20% a fragrance, such as rose, lilac or
  • compositions as described herein and where the Exemplary Composition is a paste or gel the gelling agents are dissolved in water.
  • Pharmaceutically-acceptable buffering compounds of the appropriate type and concentration such as weak acid and its conjugate base or weak base and its conjugate acid are then added to the solution of gelling agent in water until the preferred final pH range of 6.0 to 8.5 is achieved.
  • the solution containing a buffering system may be mixed with the chlorite ion source in an aqueous solution.
  • the remaining ingredients e.g.
  • humectants sweetening agents, coloring agents, abrasive agents, fluoride ion source, flavoring agent(s), emollient agents, suspending or emulsifying agents, additional deionized or purified water, and other ingredients as described above and as applicable, are added one by one in appropriate amounts to maintain the final pH of the overall formulation in the range of 6.0 to 8.5.
  • the N-acyl sarcosinate may be added as a last ingredient while preparing the composition. All compounding may occur at ambient temperatures to maintain the stability of the composition.
  • the base compound selected may be dissolved in deionize or purified water in a separate preparation.
  • This solution may be mixed with the chlorite ion source in an aqueous solution.
  • the remaining ingredients e.g. sweetening agents, flavoring agents, fluoride ion source, additional deionized or purified water, and/or other ingredients as described above and as applicable, are added one by one in appropriate amounts.
  • the N-acyl sarcosinate such as sodium lauroyl sarcosinate may be added prior to adding the weak acid while preparing the composition.
  • the appropriate amount of weak acid may be dissolved in water and the appropriate quantity may be mixed with the composition to maintain the final pH of the overall formulation in the range of 6.0 to 8.5.
  • the base compound and the weak acid of the composition constitute the buffering system as defined herein. All compounding may be required to occur at ambient temperatures to maintain the stability of the composition.
  • the method for preparation follows the method for oral rinse composition taught above, wherein additional ingredients such as dispersing agents, humectants, or preservatives are mixed with the composition prior to adjusting the pH of the final composition in the range of 6.0 to 8.5.
  • Toothpaste compositions and ingredients thereof tested are summarized in Table 1.
  • Table 2 provides a summary of the percentage weight to total weight of each ingredient in Toothpastes A to H.
  • Na 3 HP0 4 Trisodium phosphate.
  • Na 2 HP0 4 Disodium hydrogen phosphate.
  • NaH 2 P0 4 Sodium dihydrogen phosphate.
  • Example 2 Accelerated stability testing of Toothpastes A, B, C. and D.
  • Toothpaste A was prepared following the teachings of U.S. Patents 5,200,171, 5,348,734, and 5,489,435. pH of the composition containing stabilized chlorine dioxide was adjusted using only one pH adjusting agent, which is a. phosphate salt, trisodium phosphate. 5 Toothpaste A contained glycerol and sorbitol as humectants.
  • Toothpaste B was prepared following the teachings of U.S. Patent Application U.S. 2011/0318282. Toothpaste B contained sorbitol as humectant but did not contain glycerol.
  • Toothpastes C, E, and F were prepared following the teaching as described herein and according to Exemplary Composition I, wherein the stabilized chlorine dioxide compositions 10 were free of both glycerol and sorbitol and contained N-acyl sarcosinate, an aliphatic anionic compound, such as sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and sodium myristoyl sarcosinate, respectively.
  • Toothpaste D was prepared following the teaching as described herein, that is, that it was identical to Toothpaste C except for the absence of any fluoride ion source.
  • Toothpaste G was prepared following the teaching as described herein and according to Exemplary Composition I, wherein the multi-component composition contained sorbitol and sodium lauroyl sarcosinate.
  • Toothpaste H was prepared following the teaching as described herein and according to Exemplary Composition I, wherein the stabilized chlorine dioxide composition was free of 20 sorbitol and an aliphatic anionic compound.
  • Toothpaste C and Toothpaste D provide much greater shelf-life stability than Toothpaste A and Toothpaste B as taught by prior art. Only 16.6% loss of stabilized chlorine dioxide in 3 months was observed for Toothpaste C and Toothpaste D. In contrast, Toothpaste A and Toothpaste B exhibited 96.7% and 57.0% loss of stabilized chlorine dioxide, respectively, in 3 months. The 75.3% loss of stabilized chlorine dioxide from Toothpaste A in 1 month demonstrates that the shelf life stability of Toothpaste A is less than 4 months at room temperature.
  • Toothpaste A and Toothpaste B do not provide shelf life stability of stabilized chlorine dioxide for a reasonable period of time, as defined herein, that is desirable for an over-the-counter consumer product.
  • 25.0% and 33.3% losses of stabilized chlorine dioxide in Toothpaste C and Toothpaste D after six months at 40 °C, respectively, indicate that Toothpaste C and Toothpaste D have a shelf life of at least 24 months (2 years) at room temperature.
  • Toothpaste C and Toothpaste D are believed to be attributed to the inclusion of an aliphatic anionic compound in the multi-component composition, such as sodium lauroyl sarcosinate.
  • an aliphatic anionic compound such as sodium lauroyl sarcosinate.
  • the achieved stability of the chlorine dioxide in Toothpaste C and Toothpaste D is an unexpected result based on the tendency of chlorine dioxide to decompose or react with other components.
  • the toothpaste embodiments demonstrated a stable shelf-life for a single-phase composition comprising an oxidative compound, an aliphatic anionic compound, a buffering system, and carriers of the composition.
  • Toothpaste C and D were stable for a reasonable period of time, e.g., from the time of compounding to a normal time of usage for topical OTC oral care products.
  • the discovery of the effect of sodium lauroyl sarcosinate in increasing the stability of stabilized chlorine dioxide in Toothpaste C and Toothpaste D of Exemplary Composition I compared to Toothpaste A and Toothpaste B of the prior art is an unexpected result.
  • Toothpaste compositions containing N-acyl sarcosinate compounds such as sodium lauroyl sarcosinate (Toothpaste C), sodium cocoyl sarcosinate (Toothpaste E), and sodium myristoyl sarcosinate (Toothpaste F), as discussed in Exemplary Composition I were prepared and tested for their stability. Additionally, toothpaste containing N-acyl sarcosinate and sorbitol (Toothpaste G) and that does not contain sorbitol as well as N-acyl sarcosinate (Toothpaste H) were prepared and tested for their stability. The results are summarized in Table 4.
  • the stability for 3 months at 40 ⁇ 1 °C and 70-75% RH corresponds to 1 year of shelf life at room temperature.
  • the loss of stabilized chlorine dioxide in 3 months at 40 ⁇ 1° C and 70-75% RH for toothpastes A and B prepared following teachings of prior art was 96.7% and 57.0%, respectively. Measurement variability in estimation of chlorine dioxide by titration method is about 10%.
  • N-acyl sarcosinate compounds significantly enhanced the stability of stabilized chlorine dioxide. Toothpaste G that contains both sorbitol and sodium lauroyl sarcosinate exhibited 9.5% loss in stabilized chlorine dioxide in 3 months at 40 ⁇ 1° C and 70-75% RH. Similarly, Toothpaste H that does not contain sorbitol exhibited 9.5% loss in stabilized chlorine dioxide in 3 months at 40 ⁇ 1° C and 70-75% RH. The results confirm prior art that polyhydroxy compounds such as sorbitol and glycerin react with chlorite salts thereby resulting in unstable compositions.
  • Viscosity of Toothpaste H was significantly lower (713 cp) compared to other toothpaste preparations, particularly Toothpastes A through F (range 1263 cp - 1625 cp). Further, Toothpaste H did not form a uniform ribbon of toothpaste and did not hold or rest very well on a toothbrush. Such preparation does not meet the consumer goodness characteristics for a consumer product. On the other hand, viscosity of Toothpaste G was significantly higher (2306 cp) compared to other toothpaste preparations, particularly Toothpastes A through F (range 1263 cp - 1625 cp).
  • Toothpaste G was hard to squeeze out from the tubes at its viscosity and did not form a uniform ribbon. Accordingly, this level of viscosity renders it unsuitable as toothpaste.
  • Toothpastes C, D, E and F exemplify the stability, shelf-life and viscosity characteristics of a desired toothpaste embodiment.
  • Test Products US Pharmacopoeia Reference Standard for fluoride toothpaste i.e. Fluoride Dentifrice: Sodium Fluoride/Silica, Catalog No. 127752 was procured from US Pharmacopoeia store, 12601 Twinbrook Parkway, Rockville, MD 20852-1790. Crest 3D White Mild Mint and Colgate Total Advanced Whitening Toothpaste were purchased from a local store. Toothpaste B was prepared following the teachings of U.S. Patent Application U.S. 2011/0318282. Toothpaste C was prepared following the teaching as described herein and according to Exemplary Composition I.
  • Specimen Preparation Enamel specimens (3 mm diameter) were removed from extracted bovine teeth and mounted in rods. The specimens were ground and polished to a high luster with Gamma Alumina using standard methods. Eighteen specimens per group were prepared for this study.
  • Remineralizing Solution Pooled Human Saliva (collected fresh from multiple donors, pooled and kept frozen until time of use) was used as the remineralizing solution. Fifteen (15) ml of remineralizing solution was placed into color codes 30 ml treatment beakers. Fresh saliva was used each day (changed during the acid challenge period).
  • Treatment Slurries During the treatment period, the specimens were immersed in dentifrice slurries to simulate daily brushing. The slurries were prepared by adding 5.0 g of Toothpaste B or Toothpaste C to 10 g of deionized water in a beaker with a magnetic stirrer. Fresh slurries were prepared for each of the two carriers just prior to each treatment.
  • Treatment Regimen The cyclic treatment regimen consisted of a 4.0 hour/day acid challenge in the lesion forming solution described above with four, one-minute dentifrice treatment periods. After the treatments, the specimens were rinsed with running distilled water and then replaced back into the human saliva. The remaining time ( ⁇ 20 hours) the specimens were in the human saliva. The regimen was repeated for 10 days and interim Surface Micro-Hardness (SMH) measurements were obtained. The specimens were then subject to an additional 10 days of the treatment regimen for a total of 20 days.
  • the treatment schedule used for this experiment was as follows (on the first day, Step 1 was not given; the test began with one hour in human saliva to permit pellicle development prior to any treatments):
  • Step 1 - 8:00 a. m.-8:() l a.m. Dentifrice treatment
  • Step 2 - 8:01 a. m. -9: ()() a.m. Remineralizing treatment
  • Step 3 - 9:00 a. m.-9:() l a.m. Dentifrice treatment
  • Step 4 - 9:01 a.m.-10:00 a.m. Remineralizing treatment
  • Step 5 - 10:00 a.m.-2:00 p.m. Acid challenge
  • Step 6 - 2:00 p. m. -3: 00 p.m. Remineralizing treatment
  • Step 7 - 3:00 p.m. -3:01 p.m. Dentifrice treatment
  • Step 8 - 3:01 p.m. -4:00 p.m. Remineralizing treatment
  • Step 9 - 4:00 p.m. -4:01 p.m. Dentifrice treatment
  • Step 10 - 4:01 p.m.-8:00 a.m. Remineralizing treatment
  • Step 11 Back to Step 1
  • Fluoride Analysis At the end of the 20-day treatment regimen, the fluoride content of each enamel specimen was determined using the micro-drill technique to a depth of 100 ⁇ . Fluoride data were calculated as ⁇ g F/cm 3 ⁇ g F X dilution factor / volume of drilling).
  • Toothpaste C exhibited 62.3 % more fluoride uptake into incipient lesioned enamel compared to Toothpaste B of U.S. Patent Application U.S. 2011/0318282 (Table 6). Also, the fluoride uptake by Toothpaste C was 96.1%, 107.7%, and 303.3% higher than US Pharmacopoeia Reference Dentifrice, Colgate Total Advanced Whitening, and Crest 3D White Mild Mint toothpastes, respectively (Table 6). Combined effect of sodium lauroyl sarcosinate and stabilized chlorine dioxide in enhancing fluoride uptake in tooth enamel by Toothpaste C compared to Toothpaste B of prior art, US Pharmacopoeia Reference Material, and commercial products is an unexpected result.
  • Toothpaste C exhibited 63.2 % more remineralization after 20 days compared to Toothpaste B of U.S. Patent Application U.S. 2011/0318282 (Table 7). Also, the remineralization after 20 days by Toothpaste C was 37.6%, 80.9%, and 103.0% higher than US Pharmacopoeia Reference Dentifrice, Colgate Total Advanced Whitening, and Crest 3D White Mild Mint toothpastes, respectively.
  • Toothpaste B was prepared following the teachings of U.S. Patent Application U.S. 2011/0318282. Toothpaste C was prepared following the teaching as described herein.
  • the American Dental Association (ADA) reference material was procured from Odontex Inc., Lawrence, Kansas, USA.
  • Specimen Preparation Bovine, permanent, central incisors were cut to obtain labial enamel specimens approximately 10 X 10 mm.
  • the enamel specimens were embedded in an autopolymerizing methacrylate resin so that only the enamel surfaces were exposed.
  • the enamel surfaces were then smoothed and polished on a lapidary wheel and lightly etched to expedite stain accumulation and adherence. They were placed on a rotating rod (-37 °C incubator), which alternately exposed them to air and to a solution having PGY broth, tea, coffee, mucin, FeCl 3 , and Micrococcus luteus.
  • the staining broth was changed and specimens were rinsed daily until a uniform stain had accumulated. After approximately seven days, a darkly stained pellicle film was apparent on the enamel surfaces. Specimens were rinsed, allowed to air dry, and refrigerated until used. All products were tested using specimens prepared at the same time.
  • Scoring and Set-Up The amount of in vitro stain was graded photometrically using only the L value of the L*a*b* scale using a spectrophotometer (Minolta CM2600d). The area of the specimens scored was a 1/4-inch diameter circle in the center of the 10 X 10 mm enamel. Specimens with scores between 30 and 42 (30 being more darkly stained) were used. On the basis of these scores, the specimens were divided into groups with each group having approximately the same average baseline score.
  • the mean, standard deviation and SEM for each test group were then calculated using the individual PCR values. The larger the PCR value, the greater the amount of stained pellicle removed from the enamel surface in this test. Data exhibiting outlier values was not considered for calculating pellicle cleaning ratio. The mean and SEM for each group was then calculated using the individual cleaning ratios. Data was analyzed using a one-way analysis of variance model (IBM SPSS Statistics 24 Software). Data was further analyzed doing all pairwise multiple comparison procedures (Student-Newman-Keuls method). All analyses were done with the significance level set at 0.05.
  • the mean pellicle cleaning ratio of Toothpaste B, Toothpaste C, and ADA Reference Material were 95.9, 101.21, and 100.0, respectively. Further, the SEM around the mean was +2.46, +2.83, and +2.85, respectively. Therefore, Toothpaste C was most effective in removing removal of stained pellicle followed by to ADA reference material and Toothpaste B. It is important to note that Toothpaste C exhibited 5.5% higher mean pellicle cleaning ratio on numerical basis compared to Toothpaste B. However, the difference was not statistically significant since the p value for the difference between the SEM around the mean for groups was >0.05. Because the testing was conducted with the routine number of replicates, the novel discovery of the current invention was not disclosed through routine testing protocol.
  • Toothpaste C was most effective in removal of stained pellicle compared to ADA reference material and Toothpaste B was affirmed with the higher number of replicates. Further, Toothpaste B was less effective in removal of stained pellicle compared to ADA reference material. Importantly, the p-value for the difference between the groups was ⁇ 0.05. Therefore, removal of stained pellicle Toothpaste C compared to Toothpaste B of U.S. Patent Application U.S. 2011/0318282 and ADA Reference Material was statistically significant.
  • Test Product Toothpaste C was prepared following the teaching as described herein.
  • Experimental Design 4x4 mm bovine enamel sections (embedded in 12x12x7 mm acrylic resin) were prepared for use in sterile 12 well tissue culture plates and sterilized by ethylene oxide (EtO). Three ml of Brain Heart Infusion broth supplemented with Yeast Extract and Vitamin K and hemin (BHI-YE) was inoculated with 50 ⁇ of an overnight culture of a mixed species whole salivary bacterial preparation in the wells of the tissue culture plate containing the sections (1 section/well). The plates were incubated for 24 hours to grow the biofilm on the enamel.
  • EtO ethylene oxide
  • BHI-YE Three ml of Brain Heart Infusion broth supplemented with Yeast Extract and Vitamin K and hemin
  • Toothpaste B was prepared following the teachings of U.S. Patent Application U.S. 2011/0318282. Toothpaste C was prepared following the teaching as described herein. Sodium chlorite was purchased from Sigma- Aldrich, 3050 Spruce St., St. Louis, MO 63103.
  • Specimen Preparation 0.02 mM phosphate buffer pH 7.0 was prepared using HPLC grade water. 200 mg of toothpaste A and toothpaste B was suspended in 3.0 ml of 0.02 mM phosphate buffer pH 7.0 and homogenized thoroughly using rotamix. The homogenous mixture was then centrifuged at 3,500 rpm for 30 minutes. Clear supernatant was collected. Aqueous toothpaste extracts were used for spectrophotometric analysis. Each toothpaste product was processed in 5 replicates. pH adjusted HPLC-grade water served as a suitable control for recording the spectra.
  • Both Toothpaste B and Toothpaste C showed two clear absorption bands located at 262 nm and 295 nm.
  • Absorption peak at 262 nm corresponds to active chlorite anion and the peak at 295 nm is attributed to hypochlorite anion generated from the decomposition of chlorite, and/or chemical reaction of chlorite with other ingredient in the toothpaste.
  • Absorbance peak of chlorite ion (CIO2 ) at 262 nm of Toothpaste B was 0.155 and that for Toothpaste C was 0.255. Higher absorbance in Toothpaste C demonstrates 64.5% higher quantity of available chlorite ion (CIO2 ) compared to Toothpaste B.
  • Toothpaste B was prepared following the teachings of U.S. Patent Application U.S. 2011/0318282. Toothpaste C was prepared following the teaching as described herein.
  • Aqueous Toothpaste Extract Preparation 0.02 mM phosphate buffer pH 7.0 was prepared using HPLC grade water. 200 mg of Toothpaste B and Toothpaste C was suspended in 3.0 ml of 0.02 mM phosphate buffer pH 7.0 and homogenized thoroughly using rotamix. The homogenous mixture was then centrifuged at 3,500 rpm for 30 minutes. Clear supernatant was collected. Aqueous toothpaste extracts thus prepared was used for the study.
  • Aqueous solutions containing 0.02 mM of sodium pyruvate and L-methionine were prepared in 0.05 mM phosphate buffer (pH 7.0) and rigorously deoxygenated via purging with Helium gas for 30 mins at ambient temperature prior to use. 1.00 ml aliquots of this solution were individually treated with equivalent volumes of aqueous extract of the toothpaste composition. The mixture was then equilibrated at a temperature of 35 °C for 30 and 60 seconds and stored at -80 °C for a maximal period of 72 hours prior to the acquisition of X H NMR spectra. 1.0 ml aliquots of sodium pyruvate or L-methionine solution treated with an equivalent volume of HPLC-grade water equilibrated and stored in the same manner served as respective control.
  • Single-pulse and/or Carr-Purcell-Meiboom-Gill (CPMG) spin-echo X H NMR spectra was acquired on a Bruker Avance AV-400 spectrometer at an operating frequency of 399.94 MHz and a probe temperature of 293 K.
  • the one- dimensional (ID) NOESY pulse sequence with presaturation of the biofluid water signal were employed throughout. Chemical shift values were referenced to the added TSP for these samples, together with the -CH 3 group signals of selected biomolecules detectable.
  • All X H NMR spectra were acquired in duplicate, a random order and an automated manner using a sample changer for continuous sample delivery. Two-dimensional (2D) shift-correlated X H- X H spectra of biofluid samples were also acquired.
  • the ratio of concentrations of acetate:pyruvate within 30 and 60 seconds of interaction with Toothpaste C was 7.36 and 3.66 fold higher compared to Toothpaste B, respectively.
  • the ratio of concentrations of methionine sulfoxide:methionine within 30 and 60 seconds of interaction with Toothpaste C was 2.34 and 2.43 fold higher compared to Toothpaste B, respectively.
  • the results demonstrate that Toothpaste C oxidized salivary biomolecules at much faster rate and in greater quantity compared to Toothpaste B.
  • Toothpaste B Lower oxidizing activity of Toothpaste B is attributed to the partial consumption of stabilized chlorine dioxide by sorbitol present in it. The results are also aligned with the lower stability of stabilized chlorine dioxide of Toothpaste B (as presented in Table 3). Combined effect of sodium lauroyl sarcosinate and stabilized chlorine dioxide in enhancing the oxidation of salivary biomolecules by Toothpaste C compared to Toothpaste B of prior art is an unexpected result. The results demonstrate that Toothpaste C was more effective at oxidizing sodium pyruvate and L-methionine over the prior art. Not to be bound by a particular theory, the increased levels of sodium chlorite seen in Example 7 may have led to the increased oxidation reaction.
  • compositions and those against which they were compared were suitable for use as a prophylactic treatment for cleaning the teeth, by applying the composition formulated as a paste to the tooth surface when disposed in a tube as employed by individuals in routine home oral hygiene procedures of tooth brushing.
  • Numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also interpreted to include all of the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of "about 1 to 5" should be interpreted to include not only the explicitly recited values of about 1 to about 5, but also include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 3 and 4 and sub-ranges such as 1-3, 2-4 and 3-5, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cosmetics (AREA)

Abstract

Certains modes de réalisation de la présente invention concernent des compositions multi-composants et des procédés pour leur utilisation pharmaceutique et cosmétique, comprenant une combinaison d'un composé anionique aliphatique, d'un composé oxydant et d'un système tampon. La source d'ions fluorure et les autres supports sont des ingrédients facultatifs. Le composé anionique aliphatique et le composé oxydant fonctionnent ensemble, en présence ou en l'absence de source d'ions fluorure, pour protéger les composés oxydants de la dégradation avant utilisation et lors de l'utilisation, et pour améliorer l'efficacité de la composition. En plus d'obtenir une plus grande stabilité, des effets combinés du composé anionique aliphatique, du composé oxydant et de la source d'ions fluorure permettent d'obtenir une absorption de fluorure améliorée, une meilleure protection de l'émail par une reminéralisation améliorée et déminéralisation réduite, une élimination accrue de la plaque dentaire, une recroissance réduite du biofilm polymicrobien, une plus grande disponibilité des ions chlorite et une oxydation efficace des biomolécules salivaires.
PCT/US2018/049302 2017-09-01 2018-09-03 Composés anioniques aliphatiques et composés oxydants de stabilité et d'efficacité améliorées pour une utilisation dans des compositions pharmaceutiques WO2019046841A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2019114126A RU2019114126A (ru) 2017-09-01 2018-09-03 Алифатические анионные соединения и окислительные соединения с улучшенной устойчивостью и эффективностью для применения в фармацевтических композициях
AU2018241206A AU2018241206A1 (en) 2017-09-01 2018-09-03 Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
CN201880002869.6A CN109843387A (zh) 2017-09-01 2018-09-03 用于药物组合物的具有改善的稳定性和功效的脂肪族阴离子化合物和氧化性化合物
CA3020197A CA3020197C (fr) 2017-09-01 2018-09-03 Composes anioniques aliphatiques et composes oxydatifs a stabilite et efficacite ameliorees destines aux compositions pharmaceutiques
EP18785801.4A EP3474951A4 (fr) 2017-09-01 2018-09-03 Composés anioniques aliphatiques et composés oxydants de stabilité et d'efficacité améliorées pour une utilisation dans des compositions pharmaceutiques
US16/133,359 US11406577B2 (en) 2017-09-01 2018-09-17 Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
US17/094,489 US11433010B2 (en) 2017-09-01 2020-11-10 N-acyl sarcosinate compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
US17/752,568 US20220280402A1 (en) 2017-09-01 2022-05-24 Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762553450P 2017-09-01 2017-09-01
US62/553,450 2017-09-01
US201862676170P 2018-05-24 2018-05-24
US62/676,170 2018-05-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/133,359 Continuation US11406577B2 (en) 2017-09-01 2018-09-17 Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
WO2019046841A1 true WO2019046841A1 (fr) 2019-03-07

Family

ID=65527843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/049302 WO2019046841A1 (fr) 2017-09-01 2018-09-03 Composés anioniques aliphatiques et composés oxydants de stabilité et d'efficacité améliorées pour une utilisation dans des compositions pharmaceutiques

Country Status (6)

Country Link
US (1) US20220280402A1 (fr)
EP (1) EP3474951A4 (fr)
CN (1) CN109843387A (fr)
AU (1) AU2018241206A1 (fr)
RU (1) RU2019114126A (fr)
WO (1) WO2019046841A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000710B2 (en) 2009-02-13 2021-05-11 Micropure, Inc. Composition and method for the generation of chlorine dioxide from the oxidative consumption of biomolecules
US11406577B2 (en) 2017-09-01 2022-08-09 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
EP3952827A4 (fr) * 2019-04-10 2023-06-07 Black Tulip Management, Inc. Compositions de rinçage buccal pour réduire des pathogènes sous-jacents et pour traiter la maladie parodontale et la mauvaise haleine chez le chien
EP3952828A4 (fr) * 2019-04-10 2023-06-07 Black Tulip Management, Inc. Compositions de rinçage buccal pour réduire les pathogènes responsables de la carie dentaire, de la parodontite et de la mauvaise haleine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112485246B (zh) * 2020-11-19 2024-04-26 重庆瑞卡威生物科技有限公司 一种单项上皮组织肿瘤细胞渗液游离血红素显色液

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080247973A1 (en) * 1999-11-12 2008-10-09 Arif Ali Baig Compositions and Methods for Improving Overall Tooth Health and Appearance
US20100221198A1 (en) * 2007-07-09 2010-09-02 Micropure, Inc. Composition and Method for Preventing Oral Disease
US20100233101A1 (en) * 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
US20120034280A1 (en) * 2010-08-07 2012-02-09 Research Foundation Of State University Of New York Oral compositions comprising a zinc compound and an anti-microbial agent
WO2012051727A2 (fr) * 2010-10-01 2012-04-26 Swissdent Cosmetics Ag Compositions micellaires stables par oxydation
US20120164084A1 (en) * 2010-12-22 2012-06-28 Micropure, Inc. Composition and method to flavor oral care compositions containing a chlorine dioxide source
US8906348B2 (en) * 2010-03-31 2014-12-09 Mcneil-Ppc, Inc. Oral care compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713049B1 (en) * 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
CN102264636A (zh) * 2008-12-22 2011-11-30 微纯公司 用于减少牙齿的脱矿质的组合物和方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080247973A1 (en) * 1999-11-12 2008-10-09 Arif Ali Baig Compositions and Methods for Improving Overall Tooth Health and Appearance
US20100221198A1 (en) * 2007-07-09 2010-09-02 Micropure, Inc. Composition and Method for Preventing Oral Disease
US20100233101A1 (en) * 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
US8906348B2 (en) * 2010-03-31 2014-12-09 Mcneil-Ppc, Inc. Oral care compositions
US20120034280A1 (en) * 2010-08-07 2012-02-09 Research Foundation Of State University Of New York Oral compositions comprising a zinc compound and an anti-microbial agent
WO2012051727A2 (fr) * 2010-10-01 2012-04-26 Swissdent Cosmetics Ag Compositions micellaires stables par oxydation
US20120164084A1 (en) * 2010-12-22 2012-06-28 Micropure, Inc. Composition and method to flavor oral care compositions containing a chlorine dioxide source

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3474951A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000710B2 (en) 2009-02-13 2021-05-11 Micropure, Inc. Composition and method for the generation of chlorine dioxide from the oxidative consumption of biomolecules
US11406577B2 (en) 2017-09-01 2022-08-09 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
EP3952827A4 (fr) * 2019-04-10 2023-06-07 Black Tulip Management, Inc. Compositions de rinçage buccal pour réduire des pathogènes sous-jacents et pour traiter la maladie parodontale et la mauvaise haleine chez le chien
EP3952828A4 (fr) * 2019-04-10 2023-06-07 Black Tulip Management, Inc. Compositions de rinçage buccal pour réduire les pathogènes responsables de la carie dentaire, de la parodontite et de la mauvaise haleine

Also Published As

Publication number Publication date
RU2019114126A3 (fr) 2022-03-30
CN109843387A (zh) 2019-06-04
US20220280402A1 (en) 2022-09-08
AU2018241206A1 (en) 2019-03-21
EP3474951A4 (fr) 2020-02-19
EP3474951A1 (fr) 2019-05-01
RU2019114126A (ru) 2021-02-01

Similar Documents

Publication Publication Date Title
US20220280402A1 (en) Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
US11406577B2 (en) Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
US6696047B2 (en) Stable oral care compositions comprising chlorite
TWI374753B (en) Oral care product and methods of use and manufacture thereof
ES2632363T3 (es) Composición farmacéutica antiséptica para la higiene bucal y el tratamiento de enfermedades bucales de origen microbiano
RU2570751C2 (ru) Средство для ухода за полостью рта, способы его применения и производства
RU2738847C1 (ru) Композиции для ухода за полостью рта и способы их применения
JP2013535450A (ja) 精油化合物の誘導体を含む組成物、及びパーソナルケア製品における使用
CN105828885B (zh) 口腔护理组合物和方法
AU2016344348B2 (en) Mouthwash products and methods
RU2400211C1 (ru) Средство для лечебно-профилактической и гигиенической обработки зубов, десен и языка
US11433010B2 (en) N-acyl sarcosinate compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
RU2713948C2 (ru) Композиция для ухода за полостью рта
US20160000680A1 (en) Oral Care Compositions Containing Deoxy Sugar Antimetabolites
RU2524631C2 (ru) Изменение цвета содеращих халкон препаративных форм по уходу за ротовой полостью
WO2024133393A1 (fr) Composition de soin buccal contenant des polymères cellulosiques
EP4044995A1 (fr) Composition de soins buccaux
WO2016106071A1 (fr) Composition de soin bucco-dentaire

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3020197

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018785801

Country of ref document: EP

Effective date: 20181024

ENP Entry into the national phase

Ref document number: 2018241206

Country of ref document: AU

Date of ref document: 20180903

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE